Pluri Inc Share Price Today: Live Updates & Key Insights
Pluri Inc share price today is $3.23, up -3.29%. The stock opened at $3.33 against the previous close of $3.34, with an intraday high of $3.33 and low of $3.32.
Pluri Inc Share Price Chart
Pluri Inc Share Price Performance
Pluri Inc Institutional Holdings
Pluri Inc Market Status
Pluri Inc Fundamentals
Market Cap 34.09 M
PB Ratio 306.5571
PE Ratio 0.0
Enterprise Value 56.33 M
Total Assets 38.68 M
Volume 3698
Pluri Inc Company Financials
About Pluri Inc & investment objective
Company Information Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to coronavirus Disease (COVID-19), peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and is in Phase I clinical trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform. It also offers cell manufacturing services and cell-based coffee; and develops and commercializes cultivated meat products. The company operates in the field of regenerative medicine, food tech, immunotherapy, CDMO, and AgTech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
Organisation Biotechnology
Employees 127
Industry Biotechnology
CEO Mr. Yaacov Yanay
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:
Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*
Take your next step
